Latest News
Conference Coverage
Ivosidenib leads to complete responses in 32% of IDH1-mutated relapsed/refractory AML
Ivosidenib is "likely to become the new standard of care treatment" for patients with IDH1-mutant relapsed-refractory AML.
Conference Coverage
Tumor analysis: Test all MSI-high patients for Lynch Syndrome
High microsatellite instability predicts LS across numerous tumor types, indicating a need for expanded LS testing in MSI-high patients.
Conference Coverage
Equal treatment, equal or better prostate cancer outcomes for black men
CHICAGO - “The nihilism associated with prostate cancer in African-American men is not supported by this really interesting work.”
Video
A blood test to detect lung cancer inches toward the clinic
CHICAGO - Dr. Geoffrey R. Oxnard discusses interim results from the Circulating Cell-Free Genome Atlas project and ongoing work to bring the blood...
Conference Coverage
Heading down the wrong pathway in advanced breast cancer?
CHICAGO - Dr. Harold Burstein questions whether the PI3K pathway is worth pursuing, despite positive results from SANDPIPER.
Conference Coverage
Metastatic colorectal cancer chemo costs double in Washington vs. British Columbia
CHICAGO - Dr. Todd Yezefski discusses the drivers of cost disparities and implications for policy makers.
Conference Coverage
Geriatric assessments enhance patient care in advanced cancer
CHICAGO - Dr. Supriya Mohile discusses study results indicating that geriatric assessments improve communication and boost patient satisfaction....
Video
Stronger abiraterone response in mCRPC seen in black men
CHICAGO – Lead study author Dr. Daniel George discusses issues surrounding access to the standard of care for advanced prostate cancer.
Conference Coverage
Head and neck cancers: Women less commonly receive intensive chemo
CHICAGO - Senior study author Dr. Jed A. Katzel discusses ongoing research to understand the reasons behind the apparent disparities.
News
FDA grants priority review to first-line SAA treatment
Eltrombopag is being evaluated for first-line treatment of severe aplastic anemia with standard immunosuppressive therapy.
Conference Coverage
Ibrutinib plus rituximab amped PFS in Waldenström’s
The results make ibrutinib plus rituximab “a new standard of care” for the disease.